Development of Wearable Systems for Ubiquitous Healthcare Service Provisioning

This paper reports on the development of a wearable system using wireless biomedical sensors for ubiquitous healthcare service provisioning. The prototype system is developed to address current healthcare challenges such as increasing cost of services, inability to access diverse services, low quality services and increasing population of elderly as experienced globally. The biomedical sensors proactively collect physiological data of remote patients to recommend diagnostic services. The prototype system is designed to monitor oxygen saturation level (SpO2), Heart Rate (HR), activity and location of the elderly. Physiological data collected are uploaded to a Health Server (HS) via GPRS/Internet for analysis.Comment: 6 pages, 3 figures, APCBEE Procedia 7, 2013. arXiv admin note: substantial text overlap with arXiv:1309.154

Lung function, oxygen saturation and symptoms among street sweepers in Calabar, Nigeria

Chronic inhalation of dust impairs lung function and may cause respiratory symptoms. However, knowledge about the type of dust that can cause these problems is uncertain. Very little attention has been paid to the health of workers chronically exposed to dust raised by street sweeping without precautionary measures. Therefore, a study of lung function, oxygen saturation and symptoms among female street sweepers and their control groups in Calabar, Nigeria was carried out. Ventilatory function tests were done using 200 female street sweepers whose length of service was less than two years and 200 sex, age, weight, and height - matched external controls who were not exposed to any known air pollutant. The percentage of oxygen saturation( SPO2) of both the subjects and their control population was determined using a pulse oximeter. Respirable dust level in the test sites was 0.194 ± 0.002mg/m3 and it was significantly higher (

Timing Analysis of Body Area Network Applications

Body area network (BAN) applications have stringent timing requirements. The timing behavior of a BAN application is determined not only by the software complexity, inputs, and architecture, but also by the timing behavior of the peripherals. This paper presents systematic timing analysis of such applications, deployed for health-care monitoring of patients staying at home. This monitoring is used to achieve prompt notification of the hospital when a patient shows abnormal vital signs. Due to the safetycritical nature of these applications,worst-case execution time (WCET) analysis is extremely important

Ear-Lead Multiple Smart Bio Sensor System in M-health

In this paper, we present a multi-parameter wearable sensor system within a smartphone to enable a real-time unobtrusive monitoring of core body temperature, electrocardiogram (ear-lead ECG), and blood oxygen saturation (SpO2) on ambulatory patients. Clinical researches illustrating that continuing accurate measurements of core body temperature are crucial to investigate human thermoregulation in ambulatory environment and during activity. On the other part, ECG remains the mainstay test for primary diagnosis and survival analysis of the heart diseases. We implement a wireless multisensory system that measures both the tympanic temperature inside the ear and ECG data from an ear and an arm. The behind-the-Ear device makes desirable to measure ECG data without any chest belt and allow patient move around freely. The proposed Bluetooth device has similarity the form factor of a hearing aid and is wirelessly connected to a smartphone for data transmission and displaying. This device not only gives the doctors access to the core temperature and ECG data in real time, but the device can be controlled – removed and reapplied – by the patient at any time, thus increasing the performance of personal health applications

A Low Cost Wearable Medical Device for Vital Signs Monitoring in Low-Resource Settings

Medical devices are often expensive, so people in low-income countries cannot afford them. This paper presents the design of a low-cost wearable medical device to measure vital signs of a patient including heart rate, blood oxygen saturation level (SpO2) and respiratory rate. The wearable medical device mainly consists of a microcontroller and two biomedical sensors including airflow thermal sensor to measure respiratory rate and pulse oximeter sensor to measure SpO2 and heart rate. We can monitor the vital signs from a smartphone using a web browser through IEEE802.11 wireless connectivity to the wearable medical device. Furthermore, the wearable medical device requires simple management to operate; hence, it can be easily used. Performance evaluation results show that the designed wearable medical device works as good as a standard SpO2 device and it can measure the respiratory rate properly.  The designed wearable medical device is inexpensive and appropriate for low-resource settings. Moreover, as its components are commonly available in the market, it easy to assembly and repair locally

Physiological parameters for Prognosis in Abdominal Sepsis (PIPAS) Study : a WSES observational study

BackgroundTiming and adequacy of peritoneal source control are the most important pillars in the management of patients with acute peritonitis. Therefore, early prognostic evaluation of acute peritonitis is paramount to assess the severity and establish a prompt and appropriate treatment. The objectives of this study were to identify clinical and laboratory predictors for in-hospital mortality in patients with acute peritonitis and to develop a warning score system, based on easily recognizable and assessable variables, globally accepted.MethodsThis worldwide multicentre observational study included 153 surgical departments across 56 countries over a 4-month study period between February 1, 2018, and May 31, 2018.ResultsA total of 3137 patients were included, with 1815 (57.9%) men and 1322 (42.1%) women, with a median age of 47years (interquartile range [IQR] 28-66). The overall in-hospital mortality rate was 8.9%, with a median length of stay of 6days (IQR 4-10). Using multivariable logistic regression, independent variables associated with in-hospital mortality were identified: age > 80years, malignancy, severe cardiovascular disease, severe chronic kidney disease, respiratory rate >= 22 breaths/min, systolic blood pressure 4mmol/l. These variables were used to create the PIPAS Severity Score, a bedside early warning score for patients with acute peritonitis. The overall mortality was 2.9% for patients who had scores of 0-1, 22.7% for those who had scores of 2-3, 46.8% for those who had scores of 4-5, and 86.7% for those who have scores of 7-8.ConclusionsThe simple PIPAS Severity Score can be used on a global level and can help clinicians to identify patients at high risk for treatment failure and mortality.Peer reviewe

Non-invasive pulmonary artery pressure estimation by electrical impedance tomography in a controlled hypoxemia study in healthy subjects.

Pulmonary hypertension is a hemodynamic disorder defined by an abnormal elevation of pulmonary artery pressure (PAP). Current options for measuring PAP are limited in clinical practice. The aim of this study was to evaluate if electrical impedance tomography (EIT), a radiation-free and non-invasive monitoring technique, can be used for the continuous, unsupervised and safe monitoring of PAP. In 30 healthy volunteers we induced gradual increases in systolic PAP (SPAP) by exposure to normobaric hypoxemia. At various stages of the protocol, the SPAP of the subjects was estimated by transthoracic echocardiography. In parallel, in the pulmonary vasculature, pulse wave velocity was estimated by EIT and calibrated to pressure units. Within-cohort agreement between both methods on SPAP estimation was assessed through Bland-Altman analysis and at subject level, with Pearson's correlation coefficient. There was good agreement between the two methods (inter-method difference not significant (P > 0.05), bias ± standard deviation of - 0.1 ± 4.5 mmHg) independently of the degree of PAP, from baseline oxygen saturation levels to profound hypoxemia. At subject level, the median per-subject agreement was 0.7 ± 3.8 mmHg and Pearson's correlation coefficient 0.87 (P < 0.05). Our results demonstrate the feasibility of accurately assessing changes in SPAP by EIT in healthy volunteers. If confirmed in a patient population, the non-invasive and unsupervised day-to-day monitoring of SPAP could facilitate the clinical management of patients with pulmonary hypertension

US201 Study: A Phase 2, Randomized Proof-of-Concept Trial of Favipiravir for the Treatment of COVID-19

Background: Favipiravir is used to treat influenza, and studies demonstrate that it has antiviral activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Methods: We performed a randomized, open-label, multicenter, phase 2 proof-of-concept trial of favipiravir in hospitalized adult patients with polymerase chain reaction (PCR)-positive coronavirus disease 2019 (COVID-19). Patients were randomized to standard of care (SOC) or favipiravir treatment (1800mg per os twice a day [b.i.d.] on day 1, followed by 1000mg b.i.d. for 13 days). The primary end point was time to viral clearance on day 29. Results: Fifty patients were enrolled and stratified by disease severity (critical disease, severe disease, or mild to moderate disease). Nineteen patients were censored from the event of viral clearance based on being SARS-CoV-2 PCR-negative at the study outset, being PCR-positive at day 29, or because of loss to follow-up. Data from the 31 remaining patients who achieved viral clearance show enhanced viral clearance in the favipiravir group compared with the SOC group by day 29, with 72% of the favipiravir group and 52% of the SOC group being evaluable for viral clearance through day 29. The median time to viral clearance was 16.0 days (90% CI, 12.0 to 29.0) in the favipiravir group and 30.0 days (90% CI, 12.0 to 31.0) in the SOC group. A post hoc analysis revealed an effect in the subgroup of patients who were neutralizing antibody-negative at randomization. Treatment-emergent adverse events were equally distributed between the groups. Conclusions: We demonstrate that favipiravir can be safely administered to hospitalized adults with COVID-19 and believe that further studies are warranted. ClinicalTrialsgov registration: NCT04358549